Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatments have expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), dominating current treatment of nonmetastatic CRPC and hormone-sensitive prostate cancer (HSPC). The continued uptake of hormonal therapies, plus the expected label expansions of targeted agents (e.g., Janssen / GlaxoSmithKline’s Akeega, Pfizer’s Talzenna, Novartis’ Pluvicto) and anticipated approvals of emerging therapies (e.g., POINT Biopharma’s 177Lu-PNT2002 and Exelixis / Genentech’s Cabometyx + Tecentriq), will drive robust market growth over the 2022-2032 forecast period.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
KEY FEATURES
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.